The Bull Rankings scorecard — our quality-growth score is 75.4 / 100, built from three pillars scored 0–100: Quality 91, Growth 80, Value 59 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 7% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Laureate Education’s quality‑growth score of 75.4 is anchored by a Quality pillar of 91. That number tells us the company is delivering solid returns: a profit margin of 17.6 % and an ROE of 28.2 % in the latest quarter. The market price of $35.88 sits comfortably below the 52‑week high of $40.92, and the analyst consensus of $41.21 for the next year suggests modest upside. The Value pillar of 59 indicates the stock is on the cheaper side of its sector peers, but not a bargain. The strongest signal from our model is “Buying back stock”, a classic sign that management believes the shares are undervalued and that cash is being deployed efficiently. In short, the thesis is that Laureate is a high‑margin, high‑return education operator whose shares are currently underappreciated.
What the business actually is
Laureate Education operates a portfolio of higher‑education institutions across Mexico, Peru, and the United States. It offers undergraduate, graduate, and specialized degree programs in medicine and health sciences, engineering and information technology, and business and management. Programs are delivered through campus‑based, online, and hybrid modalities, and the company also runs universities, technical‑vocational institutions, and high‑school education services. The revenue engine is driven by tuition and related fees from these diverse programs, with the health sciences and engineering tracks pulling the most growth in recent quarters.
Why it can (or can't) keep compounding
The durability of Laureate’s business lies in its high operating leverage and strong brand network. A profit margin of 17.6 % in the latest quarter reflects disciplined cost control across multiple campuses and program types. The company’s debt‑to‑equity of 0.64 shows it can finance expansion without overleveraging, while a beta of 0.44 indicates lower volatility than the broader market. The “Durable high returns” signal from our model confirms that capital deployed in new campuses or online platforms is generating consistent earnings. Competitors cannot copy Laureate’s integrated delivery model quickly because it relies on a geographically diversified network and a reputation for specialized health and engineering curricula that has been built over decades. Switching costs for students—particularly in professional fields—are high, reinforcing a moat that protects market share.
The valuation question
The current P/E of 16.2 and a PEG of 1.01 suggest the market is pricing in modest growth. Our reverse‑DCF analysis shows that the price implies a free‑cash‑flow growth of about 7 % a year in year 1, fading to 3 % by year 10. This starting rate is lower than the trailing revenue growth of 17.9 %. In plain terms, the market is already pricing in a slowdown: it expects the business to grow at a pace that is below what it just delivered. The implied growth is therefore pessimistic relative to recent performance. If the company can sustain its 17.9 % revenue growth, the stock would be undervalued; if growth stalls, the price already reflects that risk.
The bear case
The most compelling skeptic points to the Value pillar of 59. While the stock is cheaper than some peers, it is not a bargain, and the reverse‑DCF implied growth of 7 % is significantly lower than the 17.9 % revenue growth. If Laureate cannot maintain its high margins or if student demand in health sciences and engineering wanes, the company could see a margin squeeze. A concrete signal that would confirm this scenario is a drop in the profit margin below 15 % or a decrease in revenue growth to below 10 % in the next quarter.
What would change our mind
- Margin deterioration: If the profit margin falls below 15 %, the Quality pillar would weaken, eroding the justification for the current price.
- Revenue growth slowdown: A decline in revenue growth to below 10 % would invalidate the optimistic growth narrative and push the reverse‑DCF implied growth higher, making the stock overvalued.
- Debt escalation: An increase in debt‑to‑equity beyond 0.80 would raise leverage concerns and could force higher interest expenses, compressing returns.
If any of these thresholds are breached, the thesis would shift from a bullish stance to a more cautious view.